Multiple MicroPort® Products Receive Approvals in the International Market

Shanghai, China, 08 January 2024 — Recently, MicroPort® received approvals for several products in the global market, benefiting more patients around the world.

MicroPort® Endovastec™’s products have received consecutive approvals for markets in two Central Asian countries. Notably, the Minos® Abdominal Aortic Stent-Graft and Delivery System has been registered and approved in Kazakhstan. Furthermore, in Uzbekistan, a total of three products, including the Hercules™ Thoracic Stent Graft with Low Profile Delivery System and the Hercules® Balloon Inflation Catheter, have also gained approval. This marks a significant milestone as it represents the inaugural approval of MicroPort® Endovastec™ products in both Kazakhstan and Uzbekistan.

MicroPort® CardioFlow’s second-generation balloon catheter, the Alwide® Plus Balloon Catheter (Alwide® Plus), has recently been approved by the Saudi Food & Drug Authority. Both the Alwide® and Alwide® Plus have been adopted in over 580 hospitals worldwide since their approvals. Additionally, progress is underway for the registration of MicroPort® CardioFlow’s VitaFlow Liberty® Transcatheter Aortic Valve and Retrievable Delivery System in Saudi Arabia.

About MicroPort® Endovastec™

Founded in 2012, Endovastec™ (Shanghai MicroPort Endovascular MedTech Group Co., Ltd.; SSE: 688016), an associated company of MicroPort® (MicroPort Scientific Corporation; HKEX: 00853), is a global medical device company focusing on R&D, manufacturing, and commercialization of aortic and peripheral vascular interventional devices. Endovastec™'s product portfolio includes thoracic and abdominal aortic stent grafts, stent grafts in surgical operation, peripheral vascular stents, and drug-coated PTA balloon catheters. Endovastec™ breaks barriers and accelerates innovation to provide trustworthy and universal access to state-of-the-art solutions for prolonging and reshaping life, and to build a people-centric enterprise as a global leader of evolving and emerging medical technologies through continuous innovation.

More information is available at

About MicroPort® CardioFlow

Founded in 2015, MicroPort® CardioFlow (MicroPort CardioFlow Medtech Corporation; HKEX: 02160), an associated company of MicroPort® (MicroPort Scientific Corporation; HKEX: 00853), is a leading medical device company focusing on research, development, and commercialization of innovative transcatheter and surgical solutions for valvular heart disease. The self-developed second-generation Transcatheter Aortic Valve Implantation (TAVI) product VitaFlow Liberty™ is the world’s only commercialized motorized retrievable system. In addition to the TAVI products, MicroPort® CardioFlow has also established a strategic R&D pipeline covering Transcatheter Mitral Valve (TMV) therapies, Transcatheter Tricuspid Valve (TTV) therapies and surgical accessories via independent development and collaboration with global partners. MicroPort® CardioFlow strives to provide total solutions for structural heart diseases, dedicated to providing high quality therapeutic solutions to patients and physicians across the globe.

More information is available at